UBS analyst Michael Lasser lowered the firm’s price target on WW to $3 from $9 and keeps a Neutral rating on the shares. While WW’s core member base is increasing modestly with the hopes of converting to Clinical, sentiment was negatively impacted by the announcement that Director Oprah Winfrey decided not to stand for re-election at the company’s upcoming annual meeting of shareholders to be held in May, the analyst tells investors in a research note. The firm thinks the risk/reward remains balanced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WW:
- Oprah Winfrey Exits, WW International Board Downsizing
- WW International, Inc. Announces Fourth Quarter and Full Year 2023 Results
- WW International, Inc. Announces Upcoming Oprah Winfrey Board Transition
- WW Earnings this Week: How Will it Perform?
- Short Report: Bears boost WW exposure ahead of earnings after marketing debacle